

Poster presentation

Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophy

G Guaraldi*, S Zona, R D'Amico, N Squillace, G Orlando, C Stentarelli and R Esposito

Address: University of Modena and Reggio Emilia, Modena, Italy

* Corresponding author

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Published: 10 November 2008

Journal of the International AIDS Society 2008, **11**(Suppl 1):P125 doi:10.1186/1758-2652-11-S1-P125

This abstract is available from: <http://www.jiasociety.org/content/11/S1/P125>

© 2008 Guaraldi et al; licensee BioMed Central Ltd.

Purpose of the study

To assess statistical agreement of metabolic syndrome (MS) ATPIII, IDF, EGIR and AACE classification in HIV-infected patients and association with body fat redistribution.

Methods

Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic who were screened for MS and had a clinical and radiological lipodystrophy (LD) evaluation. Cohen's Kappa statistic was calculated to assess statistical agreement between different MS classifications. Logistic regression models were performed to identify factors associated with different MS classifications. (Tables 1 and 2.)

Summary of results

1,348 pts were included in the analysis.

Figure 1 depicts prevalence of metabolic syndrome according to different definition.

Conclusion

Concordance between MS classification is less than ideal. After adjusting for BMI strata, lipodystrophy phenotypes and central fat accumulation are associated with for MS diagnosis.

Table 1: K of Cohen shows a low level of agreement between MS classifications.

	EGIR	AACE	NCEP ATP-III
IDF	0.27* (64.61%)	0.07* (56.01%)	0.41* (71.66%)
EGIR		0.21* (74.33%)	0.38* (75.74%)
AACE			0.35* (81.68%)

*p-value < 0.001 Body fat changes (LD definition and objective anthropometric variables) were included in univariable and multivariable logistic analysis.

Table 2:

Variables	ATP-III Adj. OR (95% CI)	P-value	EGIR Adj. OR (95% CI)	P-value	IDF Adj. OR (95% CI)	P-value
Lipoatrophy	1.14 (0.66; 1.96)	0.63	1.20 (0.71; 2.03)	0.49	1.21 (0.79; 1.84)	0.37
Central adiposity	1.87 (0.99; 3.53)	0.054	2.88 (1.64; 4.27)	0.001	2.14 (1.21; 3.79)	0.009
Mixed form	2.06 (1.26; 3.37)	0.004	2.65 (1.64; 4.27)	<0.0001	2.12 (1.43; 3.14)	<0.0001
% fat legs (10%)	1.04 (0.82; 1.32)	0.73	0.73 (0.57; 0.93)	0.013	0.91 (0.74; 1.13)	0.41
VAT/TAT	12.35 (4.84; 31.48)	<0.0001	2.80 (1.16; 6.78)	0.022	2.37 (1.08; 5.21)	0.031
BMI						
<19	0.33 (0.13; 0.86)	0.024	0.30 (0.12; 0.78)	0.014	0.51 (0.28; 0.92)	0.027
between 19 and 25	Ref.	-	Ref.	-	Ref.	-
between 25 and 30	2.12 (1.51; 2.99)	<0.0001	2.36 (1.70; 3.28)	<0.0001	2.42 (1.76; 3.32)	<0.0001
>30	5.56 (3.04; 10.16)	<0.0001	12.38 (6.28; 24.43)	<0.0001	5.99 (3.02; 11.90)	<0.0001




Figure 1

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

